Core Insights - Kyverana Therapeutics (NASDAQ: KYTX) is preparing for multiple catalysts in the coming years, aiming to be among the first to potentially receive regulatory approval for a CAR-T therapy [2] Group 1 - The company is focused on developing CAR-T therapies, which are a type of immunotherapy used to treat certain types of cancer [2] - Kyverana Therapeutics is part of a broader trend in the biotech industry, where companies are increasingly investing in innovative therapies to address unmet medical needs [2]

Core Viewpoint - Kyverna Therapeutics, Inc. (KYTX) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for Kyverna Therapeutics indicates an expected loss of -$3.29 per share for the fiscal year ending December 2024, reflecting a year-over-year change of 96.3% [9]. - Over the past three months, analysts have raised their earnings estimates for Kyverna Therapeutics by 7.9% [9]. Zacks Rating System - The Zacks rating system is based solely on a company's changing earnings picture, which is crucial for stock price movements [2][3]. - The system classifies stocks into five groups, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of Kyverna Therapeutics to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10][11].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Kyverna Therapeutics, Inc. during its IPO on February 8, 2024, about the lead plaintiff deadline of February 7, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Kyverna common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 7, 2025 [3]. - The lawsuit claims that Kyverna's IPO registration statement and prospectus misrepresented facts regarding the clinical trial results of its lead product candidate, KYV-101, leading to investor damages when the true information was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ: KYTX).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Kyverna and certain of its o ...

LOS ANGELES, Feb. 4, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ: KYTX) for violations of the federal securities laws.Shareholders who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to contact the firm before February 7, 2025.CASE DETAILS:  Th ...

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=126263&from=4 CLASS PERIOD: T ...

Core Viewpoint - Rosen Law Firm is reminding investors of Kyverna Therapeutics, Inc. about the upcoming lead plaintiff deadline for a class action lawsuit related to the company's IPO on February 8, 2024 [1][2]. Group 1: Class Action Details - Investors who purchased Kyverna common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 7, 2025 [2]. - The lawsuit claims that Kyverna's IPO registration statement and prospectus contained misstatements and omissions regarding the clinical trial results of its lead product candidate, KYV-101 [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [3]. - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Specifics - The lawsuit alleges that Kyverna misrepresented patient "improvement" indicators while failing to disclose adverse data known at the time of the IPO, leading to artificially inflated stock prices [4]. - When the true details about the clinical trials became public, investors reportedly suffered damages [4].

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company's o ...

Core Viewpoint - A securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. on behalf of investors who purchased its common stock during the February 8, 2024 IPO, with a lead plaintiff deadline set for February 7, 2025 [1]. Group 1: Allegations Against Kyverna - The complaint alleges that Kyverna's IPO prospectus and registration statements contained materially false and misleading statements regarding the company's business, operations, and prospects [2]. - Specifically, it is claimed that Kyverna failed to disclose adverse data related to one of its clinical trials at the time of the IPO [2]. Group 2: Lead Plaintiff Process - Investors in Kyverna have until February 7, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3]. - The lead plaintiff will act on behalf of all class members in directing the litigation and is typically the investor or small group of investors with the largest financial interest [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions in state and federal courts and has a reputation for recovering billions for victims of fraud and corporate misconduct [4].

NEW YORK, Jan. 27, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public offering conducted on February 8, 2024 (the "IPO"), of the important February 7, 2025 lead plaintiff deadline.So what: If you purchased Kyverna common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.W ...